Gut microbiota: A new therapeutic target for diabetic cardiomyopathy

6Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Some studies have shown that gut microbiota plays an important role in cardiovascular diseases. Gut microbiota and its metabolites can affect the development of diabetic cardiomyopathy by regulating oxidative stress, inflammation, insulin resistance, apoptosis, and autophagy. Here, the mechanisms of gut microbiota and its metabolites resulting in diabetic cardiomyopathy are reviewed. Gut microbiota may be a new therapeutic target for diabetic cardiomyopathy.

Cite

CITATION STYLE

APA

Yuan, S., Cai, Z., Luan, X., Wang, H., Zhong, Y., Deng, L., & Feng, J. (2022, August 26). Gut microbiota: A new therapeutic target for diabetic cardiomyopathy. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.963672

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free